TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07390123: A Randomized, Double-blind, and Placebo-controlled Parallel Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN

Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 370 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,805,952

Rescue Site Savings

+$6,458,728

Unlock Full NCT07390123 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07390123 Rescue Dossier →